Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant: COVID-19 Rapid Research Funding Opportunity - Vaccines

Ottawa Hospital Research Institute

$1,936,150.00

Development of Vaccines to Prevent SARS-CoV-2 Infection of High Risk Individuals

EF 2020-21

Résumé
The physical-distancing strategy currently implemented in the Covid-19 pandemic in Canada has been very effective in preventing the vast majority of Canadians from being infected by SARS-CoV-2. This essential short-term strategy is saving lives, but paradoxically will leave most of our citizens without protective immunity and a recurrent outbreak is both predictable and likely without an effective Canadian vaccine strategy. A global effort has been initiated to identify an effective Covid-19 vaccine, testing a variety of vaccine platforms and strategies. Unfortunately, few of these are being developed, tested or manufactured in Canada leaving our population in a very perilous situation where our vaccine needs could be de-prioritized by foreign governments. This project is aimed at bringing together a multi-disciplinary team of scientists and clinicians to rapidly create and manufacture a vaccine to prevent a second wave of infections. We are using scientists and infrastructure, already available in Ottawa, Montreal, Calgary and the US (Covington Louisiana) to rapidly create, compare and contrast different vaccine strategies in animal models. Our best candidate will then be manufactured in a pure enough form to inject in humans. We will complete all of the data and regulatory documents to prepare an application to Health Canada to allow the initiation of a clinical trial in healthy volunteers.
Programme
Operating Grant: COVID-19 Rapid Research Funding Opportunity - Vaccines
Emplacement
Ontario, Canada
Type de bénéficiaire
Other
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
430635
Name
Bell John C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
COVID-19 Rapid Research - Vaccines
Projecttitle
Development of Vaccines to Prevent SARS-CoV-2 Infection of High Risk Individuals
Programtype2
Operating Grants
Orgnameinp2
Ottawa Hospital Research Institute
Cihramount2
$1,936,150
Cihrequipment2
$0
Programname2
Operating Grant: COVID-19 Rapid Research Funding Opportunity - Vaccines
Keyworddelim
Covid-19; Epitopes; Immunity; Infection; Manufacturing; Pre-Clinical; Sars-Cov-2; Vaccine
Abstract
The physical-distancing strategy currently implemented in the Covid-19 pandemic in Canada has been very effective in preventing the vast majority of Canadians from being infected by SARS-CoV-2. This essential short-term strategy is saving lives, but paradoxically will leave most of our citizens without protective immunity and a recurrent outbreak is both predictable and likely without an effective Canadian vaccine strategy. A global effort has been initiated to identify an effective Covid-19 vaccine, testing a variety of vaccine platforms and strategies. Unfortunately, few of these are being developed, tested or manufactured in Canada leaving our population in a very perilous situation where our vaccine needs could be de-prioritized by foreign governments. This project is aimed at bringing together a multi-disciplinary team of scientists and clinicians to rapidly create and manufacture a vaccine to prevent a second wave of infections. We are using scientists and infrastructure, already available in Ottawa, Montreal, Calgary and the US (Covington Louisiana) to rapidly create, compare and contrast different vaccine strategies in animal models. Our best candidate will then be manufactured in a pure enough form to inject in humans. We will complete all of the data and regulatory documents to prepare an application to Health Canada to allow the initiation of a clinical trial in healthy volunteers.
Competitiondate
202005
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bell, John C; Ilkow, Carolina S; Lapointe, Réjean; Mahoney, Douglas J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $1,936,150~ $0~